In vivo potentiation of cis-diamminedichloroplatinum (II) antitumor activity by pretreatment with sparsomycin.

Abstract

The influence of protein synthesis inhibition by sparsomycin (Sm) on in vivo cisplatin activity has been studied on BALBc X DBA2: F1 mice bearing L1210 leukemia i.p. Sm alone at the dose range from 0.5 to 3.0 mg/kg did not significantly improve animal survival. Sm potentiated cisplatin activity only when given 3 or 6 h prior to cisplatin (P less than 0.001). Sm 0.5-1.5 mg/kg 3 h prior to cisplatin resulted in a significant prolongation of animal survival (P less than 0.001) and 66% cures in each group versus 0% due to cisplatin alone. Sm pretreatment decreased weight loss due to cisplatin suggesting that it probably is able to decrease cisplatin toxicity.

• Authors: Z Zylicz, D J Wagener, H van Rennes, J M Wessels, E van der Kleijn, W J de Grip, H C Ottenheijm, L A van den Broek
• Journal: Cancer letters (Cancer Lett) Vol. 32 Issue 1 Pg. 53-9 (Jul 1986) ISSN: 0304-3835 [Print] Ireland
• PMID: 3742487 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibiotics, Antineoplastic
• Sparsomycin
• Cisplatin

Topics

• Animals
• Antibiotics, Antineoplastic (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cisplatin (administration & dosage)
• Drug Synergism
• Female
• Leukemia L1210 (drug therapy, mortality)
• Mice
• Mice, Inbred Strains
• Sparsomycin (administration & dosage)